Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

varnimcabtagene autoleucel

A preparation of adult differentiated autologous T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv), derived from the CD19-A3B1 hybridoma, linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. The autologous T cells were stimulated with anti-CD3 and anti-CD28 antibodies, expanded with interleukin (IL) 7 (IL-7) and IL-15, and transduced with a lentiviral vector containing the CAR gene construct. Upon administration, varnimcabtagene autoleucel target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19 CAR T cells ARI-0001
autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T cells ARI-0001
CD19 CAR T cells ARI-0001
CD19 CAR-T cells ARI-0001
Code name:ARI 0001
ARI-0001
ARI0001
PEI 19-187
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search